NIPT Screening Services for Trisomy Market Size (2024 – 2030)

The global NIPT Screening Services for Trisomy Market size was exhibited at USD 7.3 billion in 2023 and is projected to hit around USD 17.71 billion by 2030, growing at a CAGR of 13.5% during the forecast period from 2024 to 2030.

A blood test called non-invasive prenatal testing (NIPT) is done on expectant mothers to check for chromosomal abnormalities in the growing fetus. Trisomies, which happen when a baby has an extra copy of a chromosome, are the focus of this test. NIPT is a very reliable screening technique, but it's important to keep in mind that it's not a conclusive diagnosis. A chromosomal anomaly is not always present in negative results, nor is it always certain to be absent. Additional testing like as amniocentesis or CVS becomes required for confirmation if an NIPT result raises doubts. NIPT trisomy screening has a few benefits. It is safe, non-invasive, very accurate, and can be done as early as week nineteen in pregnancy. Expectant parents may benefit greatly from this early detection in terms of peace of mind.

Key Market Insights:

There is a notable surge in the market for trisomy screening based on NIPT. The need for precise prenatal screening techniques is being driven by the increasing public awareness of the test. Furthermore, NIPT is a clear winner over conventional, more intrusive techniques due to its non-invasive nature. The increasing frequency of Down syndrome and the growing practice of women postponing delivery until their late 30s and early 40s, when the chance of trisomy rises, both contribute to this spike. But there are some bumps in the road ahead. Continued commercial expansion may be hampered by issues like a lack of skilled individuals to administer and interpret the test and possible difficulties with insurance reimbursement.

Global NIPT Screening Services for Trisomy Market Drivers:

Enabling Anticipating Parents with Precise Screening

The field of prenatal care is changing as expectant mothers and fathers look for more advanced and dependable techniques to detect possible anomalies in the developing fetus. A greater understanding of genetic disorders and a strong demand for reliable information are driving this expanding need. In this regard, non-invasive prenatal testing, or NIPT, has become a game-changer since it provides a non-invasive, highly accurate screening tool in place of more conventional techniques. Expectant parents are likely to prioritise making educated decisions during their pregnancy, which will lead to a considerable increase in the demand for NIPT.

Emphasizes the importance of ensuring the safe use of NIPT as it becomes more widely adopted.

The market is expanding thanks in large part to public education on NIPT. As NIPT becomes more well-known and its benefits (high accuracy, non-invasive nature) are more understood, expectant parents and medical professionals are becoming more at ease with the idea of contemplating and using it for prenatal screening. Patient advocacy groups are bringing awareness to the issue and offering support, healthcare institutions are incorporating NIPT into their prenatal care options, and NIPT service providers are actively involved in promoting their services as part of this joint educational drive. This coordinated effort opens the door for NIPT's wider integration into the healthcare system and guarantees its safe use.

Global NIPT Screening Services for Trisomy Market Restraints and Challenges:

A few obstacles are preventing it from reaching its full potential. The scarcity of licensed healthcare providers with the necessary skills to explain NIPT results and assist patients in the procedure is one of the main obstacles. This can provide a barrier to accessibility and is especially common in underdeveloped areas.  Reimbursement issues provide a big obstacle. Some insurance plans may not cover NIPT, which could put a financial strain on expectant parents and possibly reduce the uptake of the test. Additionally, there should be constant discussion and serious thought given to the ethical issues raised using NIPT, such as possible discrimination based on test findings. All these elements combine to create obstacles that the market for NIPT trisomy screening services must overcome to grow steadily and fairly.

Global NIPT Screening Services for Trisomy Market Opportunities:

There are several intriguing prospects for growth in the worldwide market for NIPT screening services for trisomy.  Growing need for thorough and knowledgeable prenatal care, as expectant parents look for more sophisticated ways to identify possible problems early on. The increasing knowledge and understanding of NIPT, its advantages, and its drawbacks are driving this trend. Additionally, as technology advances, the NIPT's cost-effectiveness, accuracy, and scope are continually improved, increasing its accessibility to a larger audience. Improved reimbursement guidelines and greater accessibility can be facilitated by proactive partnerships between legislators, NIPT service providers, and healthcare professionals, especially in underprivileged areas.  The market for NIPT trisomy screening services has the potential to grow sustainably and inclusively, providing pregnant parents with essential information to help them make educated decisions throughout their pregnancies.

 NIPT SCREENING SERVICES FOR TRISOMY MARKET REPORT COVERAGE:

Global NIPT Screening Services for Trisomy Market Segmentation: By Type

• Unsaturated Polyester

• Epoxy

• Vinyl Ester Resin

• Phenolic

• Polyurethane

• Others

By application, Trisomy 21 (Down syndrome) is the largest and fastest-growing section of the NIPT screening services for the trisomy market. Its high prevalence, well-established screening protocols, and ongoing technological advancements are the reasons for its dominance, whereas the market share and growth rate for other trisomies are still lower because of their much lower prevalence and the ongoing development of targeted screening techniques.

Global NIPT Screening Services for Trisomy Market Segmentation: By End Use

• Construction

• Automotive

• Electrical and Electronics

• Oil & Gas

• Others

Because of its many benefits, cell-free DNA (cfDNA) testing is quickly replacing karyotyping as the method of choice for prenatal screening.  Pregnant mothers will find cfDNA testing to be a considerably more tempting choice than karyotyping, which entails a potentially dangerous needle insertion into the placenta or amniotic sac.  cfDNA testing retains high accuracy in identifying chromosomal abnormalities, including Down syndrome, despite this change in invasiveness, offering useful data for additional assessment.  In addition, cfDNA testing offers a simple blood draw and laboratory analysis procedure, whereas karyotyping requires specific training and has a minor miscarriage risk. 

The Hospitals & Clinics category is the largest. The broad accessibility of NIPT services in various contexts is the main factor contributing to this dominance. Due to the established patient relationships at hospitals and clinics, NIPT can be accessed more easily by pregnant moms in addition to their routine prenatal treatment. These facilities also have the equipment and know-how needed to perform NIPT procedures, such as blood collection, first test administration, and communication of preliminary results. Nonetheless, home testing is growing at the quickest rate due to rising customer preferences for accessibility and convenience. This market is anticipated to grow in the future as laws are implemented and home testing kits become more readily available.

Global NIPT Screening Services for Trisomy Market Segmentation: By Region

• North America 

• Asia-Pacific 

• Europe 

• South America 

• Middle East and Africa

With the biggest market share, North America is currently in the lead. High healthcare spending per person, early acceptance of cutting-edge technologies, and broad knowledge and adoption by both medical professionals and expectant parents are some of the factors driving this dominance. Nonetheless, the Asia-Pacific area is seeing the quickest rise, which is attributed to factors including a sizable and expanding population, rising disposable income, and greater NIPT awareness. Asia-Pacific is anticipated to maintain its quick growth in this market as long as healthcare infrastructure continues to improve, government initiatives support prenatal care, and acceptance of NIPT increases.

COVID-19 Impact Analysis on the Global NIPT Screening Services for Trisomy Market:

The COVID-19 pandemic has had a conflicting effect on the market for NIPT trisomy screening services worldwide. At first, NIPT operations temporarily decreased because of the emphasis on handling COVID-19 cases. This resulted from redistributing healthcare resources, giving COVID-19 patients priority, and possibly anticipating pregnant women's reluctance to visit hospitals during lockdowns. But in the middle of the pandemic, the pattern changed. The need for NIPT services increased during this time due to the increased emphasis on prenatal care and the rise in pregnancies. This is explained by rising fetal health concerns and the ongoing demand for non-invasive prenatal screening methods.

Recent Trends and Developments in the Global NIPT Screening Services for Trisomy Market:

The non-invasive prenatal test, known as the PreviaTest in Germany, was introduced by BGI and Eluthia (Germany). With the release of VeriSeq NIPT Solution v2, Illumina increased the scope of its NIPT platform. A deal was signed by Illumina and Pacific Biosciences for Illumina to buy Pacific Biosciences. With this acquisition, Illumina will be able to add precise long-read sequencing capabilities to its platform of sequencing solutions. Multiplicom N.V. (Belgium) was acquired by Agilent Technologies to expand its portfolio of next-generation sequencing solutions. Molecular diagnostic technologies developed and marketed by Multiplicom help identify genetic illnesses and congenital abnormalities early in pregnancy.

Key Players:

1. Illumina

2. Thermo Fisher Scientific Inc.

3. GE Healthcare

4. BGI

5. Agilent Technologies, Inc.

6. F. Hoffmann-La Roche Ltd.

7. PerkinElmer

8. Laboratory Corporation of America Holdings

9. Yourgene Health